ArticlePain research & management2026
Esketamine Alleviates Neuropathic Pain and Inflammation via miR-153-3p/AKT3 in CCI Rats.
Article in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esketamine Alleviates Neuropathic Pain and Inflammation via miR-153-3p/AKT3 in CCI Rats.Pain research & management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe analgesic effects of esketamine have been reported. MiR-153-3p is a central player in multiple pathologies of neural injury. The potential interplay between them remains unclear.
objectiveThis study investigated whether the analgesic effects of esketamine in neuropathic pain were mechanistically linked to miR-153-3p. MATERIALS AND
methodsNeuropathic pain was induced in rats through chronic constriction injury (CCI) of the sciatic nerve, followed by esketamine administration. Pain hypersensitivity was assessed by dynamic changes in paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL). MiR-153-3p expression was manipulated via intrathecal injection of lentiviral-delivered miR-153-3p mimic. RT-qPCR was employed for analysis of miR-153-3p expression and AKT3 mRNA levels. Proinflammatory cytokine levels were quantified by ELISA, while protein expression was detected using Western blot. The interaction between miR-153-3p and AKT3 was verified by RIP and luciferase reporter assays.
resultsEsketamine alleviated CCI-induced neuropathic pain by elevating PWMT and PWTL. Esketamine also reduced proinflammatory cytokine release. MiR-153-3p was significantly reduced in CCI rats, and esketamine administration effectively reversed its decline. MiR-153-3p upregulation suppressed pain hypersensitivity and proinflammatory cytokines. AKT3 was a target of miR-153-3p. AKT3 knockdown abolished the effect of MiR-153-3p inhibition on esketamine protection.
conclusionEsketamine mitigated neuropathic pain and reduced proinflammatory cytokine release through the miR-153-3p/AKT3 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.